Literature DB >> 28477538

Ischemic heart disease and rheumatoid arthritis: Do inflammatory cytokines have a role?

Samah A El Bakry1, Dalia Fayez2, Caroline S Morad2, Ahmed Mohamed Abdel-Salam3, Zeinab Abdel-Salam3, Rania H ElKabarity4, Al Hussein M El Dakrony5.   

Abstract

BACKGROUND: The increase in Rheumatoid arthritis (RA) associated mortality is predominantly due to accelerated coronary artery and cerebrovascular atherosclerosis with increased risk of ischemic heart disease about 50% in RA patients compared to controls.
OBJECTIVE: To study the pathogenesis of ischemic heart disease in RA, role of inflammatory cytokine interplay, disease activity and rheumatoid factor positivity.
METHODS: Eighty RA patients and 44 healthy controls were included. All subjects were younger than 45years for females and 55years for males with exclusion of all traditional risk factors for atherosclerosis. Interleukin (IL) 1, 6 and 18 were assessed in all subjects. RA patients fulfilled ACR/EULAR 2010 criteria and were subjected to Dobutaminestress-echocardiography, diseases activity assessed by DAS-28, X-ray hands for Larsen score and function assessment by HAQ.
RESULTS: RA patients had significantly higher serum IL 1, 6 and 18 than controls (p=0.00 in all). Thirty four (42.5%) patients had hypertensive reaction on Dobutamine-stress-echocardiography, four of them had ischemic change, and 46 (57.5%) had normal reaction. All patients with hypertensive reaction had positive RF (p=0.00), 10 had DAS-28>5.1, 20 had DAS-28 from 3.2 to5.1 and 4 were in remission (p=0.001). CRP was higher in patients with hypertensive reaction (p=0.003) while serum levels of IL1, 6 and 18 showed no significant difference. In all patients, serum levels of IL1, 6 and 18 showed significant positive correlation with VAS, HAQ and DAS-28 (p<0.001 in all). Only IL18 showed significant positive correlation with X-ray score in all patients.
CONCLUSION: Disease activity and RF positivity play an important risk factor for ischemic heart disease in RA. Serum levels of IL1, 6 and 18 did not help much in detecting patients at risk of ischemic heart disease. Better control of RA disease activity with early remission helps in preventing cardiac complications. More studies on larger number of patients are needed for better understanding of mechanism of ischemic heart disease in RA.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inflammatory cytokines; Ischemic heart disease; Rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28477538     DOI: 10.1016/j.cyto.2017.04.026

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

Review 1.  Coronary Artery Ectasia: Review of the Non-Atherosclerotic Molecular and Pathophysiologic Concepts.

Authors:  Gavin H C Richards; Kathryn L Hong; Michael Y Henein; Colm Hanratty; Usama Boles
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

2.  Circular RNA-DENND4C in H9c2 cells relieves OGD/R-induced injury by down regulation of microRNA-320.

Authors:  Jun Zhang; Tao Zhang; Wenlong Zhang; Chengwei Zou; Qian Zhang; Xiaochun Ma; Yanhui Zhu
Journal:  Cell Cycle       Date:  2020-10-22       Impact factor: 4.534

Review 3.  Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease.

Authors:  Renáta Gáspár; Dóra Halmi; Virág Demján; Róbert Berkecz; Márton Pipicz; Tamás Csont
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

4.  Cytokine Disturbances in Coronary Artery Ectasia Do Not Support Atherosclerosis Pathogenesis.

Authors:  Usama Boles; Anders Johansson; Urban Wiklund; Zain Sharif; Santhosh David; Siobhan McGrory; Michael Y Henein
Journal:  Int J Mol Sci       Date:  2018-01-16       Impact factor: 5.923

5.  Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis.

Authors:  Lydia Ntari; Maria Sakkou; Panagiotis Chouvardas; Iordanis Mourouzis; Alejandro Prados; Maria C Denis; Niki Karagianni; Constantinos Pantos; George Kollias
Journal:  Ann Rheum Dis       Date:  2018-02-23       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.